Cross-reactivity reactivity in EMIT

Similar documents
Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Procedure for Toxicology Analysis Version 7 Toxicology Unit Effective Date: 03/14/2014 Issued by Drug Chemistry Forensic Scientist Manager

Procedure for Toxicology Analysis Version 4 Toxicology Unit Effective Date: 05/10/2013. Toxicology Analysis

Urine Drug Testing Methods 3-5

Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.

The Drug Evaluation and Classification Program

Forensic Toxicology Scope of Testing and Detection Limits

Federal Trafficking Penalties (As of January 1, 1996)

Alcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082

Lyndsey Knoy, D-ABFT-FT Forensic Scientist Washington State Toxicology Laboratory.

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

Drug and Alcohol Impairment. Alabama DRE / SFST Program

Drug Profiles of Apprehended Drivers in Victoria

EDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing

Drug Testing Basics. by Erowid

NARCOTIC NOTES FLIPBOOK BY: PER:

Physician s Reference for Urine and Blood Drug Testing and Interpretation

Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey

Controlled Substance Monitoring in the Age of the Opioid Epidemic

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.

ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS

Information on Specific Drugs of Abuse

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY

Drugs Found in Medical Examiner Cases

What is a DRE. Introduction to Drugged Driving

Drug Adherence Assessment Report

INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY

The Rest of the Date Rape Drugs. Michele Glinn, Ph.D. Supervisor, Toxicology Unit Forensic Sciences Division Michigan State Police

Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens

Pinellas County Forensic Laboratory. Annual Report 2006

Urine Opioid Dependency Panel (UODP) 1

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

Observations of Drug Impaired Drivers. Winona County Deputy Chad Myers DRE/SFST Instructor Law Enforcement Phlebotomist Winona Co.

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

Laboratory Service Report

Overview of the Drug Evaluation and Classification Program April 28, 2015

The Drug Testing Process. Employer or Practice

Test Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

Your Results are Our Priority.

CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)

Glencoe Health. Lesson 3 Psychoactive Drugs

nextgen precision Test Report

Test Definition: PCDSO Pain Clinic Drug Screen, Urine

Slide 1. Slide 2. Slide 3. Definitions. Definitions. Drug-Facilitated Sexual Assault

DrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.

What is the difference between Vicoden, OxyContin, Percocet and Percodan

Types of Drugs by Physical Effect- Narcotics

Testing for Controlled Substances

Controlled Substances: Drugs. Chapter 5

Recent Developments in FRA s Post-Accident Toxicological Testing Program

Minnesota Drugged Driving Summit. Shifting Gears to Address the Challenge

COUNTY OF SAN DIEGO. Opioid Update

Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up

DRUGGED DRIVING IN MINNESOTA

Tests recently added to the NMS Labs test menu. New Tests are effective immediately.

North Carolina Drug Evaluation & Classification (DEC) Program

Drugs. January 30, , 2008 Pearson Education, Inc. Upper Saddle River, NJ 07458

Learning Objectives (Cont.) Describe the observable signs usually associated with the drug categories

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

An Introduction to Forensic Toxicology

Controlled Substances. Forensic Science

Specific Drugs of Abuse

POINT OF CARE TESTING

Chapter 23. Medicines and Drugs

Pain Medication Management Program Supports Patient Outcomes and Adherence

Schedule of Accreditation

Section 2 Class III, IV & V Pharmaceuticals Page 13

2015 Annual Physician Notice

Chapter 3 Part 2: Tolerance, dependence, addiction, & types of drugs

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

WELCOME! 12/13/2018. Today s Topic: Urine Drug Screens in OUD Treatment UW PACC

Pain Medication Management Program Monitors Patient Compliance

Lisa Booze, PharmD, CSPI

Controlled Substance Monitoring and Drugs of Abuse Testing Determination

MEDICAL POLICY No R2 DRUG TESTING

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Common Drugs of Abuse. What to look for, physical symptoms, and dangers

Hallucinogens Marijuana

A. Definition and Categories of Drugs Instructor Led Presentations B. Incidence and Characteristics of Reading Assignments

4/27/2016. About CCSA. Impaired Driving Research at CCSA. Background. Presentation Overview. Lessons Learned

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

National Problem?? DRUG DEATHS 07/15/ th School Nurses Conference 2018 Identifying the Impaired Person Causes for Fatal Crashes

DRUGS OF ABUSE

TABLE 1 Annual Prevalence of Use for Various Types of Illicit Drugs, 2015 Among Full-Time College Students 1 to 4 Years beyond High School by Gender

Annual Reports Questionnaire (ARQ) Part III: Extent, patterns and trends in drug use

SESSION XXIV DRUG COMBINATIONS

Biology 3201 Nervous System #6: Effects of Drugs at Synapses

distinguish between structural isomers (but not necessarily stereoisomers), including, but not

May Revised Urine Drug Screen Test Menu Effective mid-june Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory

Substance Abuse. Substance abuse includes the use of illegal substances, as well as the misuse of legal substances.

C O P E. Milwaukee County Opioid-Related Overdose Report MILWAUKEE COMMUNITY OPIOID PREVENTION EFFORT

Polysubstance Use & Medication-Assisted Treatment

MEDICAL POLICY Drug Testing

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Community Drug Early Warning System (CDEWS-3): Washington, DC - Site 3 of 4

Transcription:

Blood Drug Analysis at the State Bureau of Investigation Crime Laboratory Richard W. Waggoner, Jr. Sample Requirements 2-10 ml gray top vacutainers At least 10 ml of urine sample for drug facilitated sexual assault Keep refrigerated as much as possible and transfer as soon as reasonably possible. Administrative Requirements for Blood Drug Analysis 1

Screening Not Confirmatory EMIT Enzyme Multiplied Immunoassay Technique (all blood drug cases) ELISA Enzyme Linked Immunosorbent Assay (when methamphetamine/mdma is requested) 2

Drug Classes Screened by EMIT Benzoylecgonine (cocaine metabolite) 50 ng/ml Barbiturates 1000 ng/ml Phenobarbital Benzodiazepines i 50 ng/ml Nordiazepam Opiates 50 ng/ml Morphine Cannabinoids 20 ng/ml (THC-COOH) COOH) Methadone 50 ng/ml (recently added screen) Cross-reactivityreactivity Cross-reactivity reactivity in EMIT Example Benzodiazepine Cutoff set with 50 ng/ml Nordiazepam standard Case contains Alprazolam Case contains Clonazepam ELISA ELISA Screen Methamphetamine/MDMA 50 ng/ml d-methamphetamine when requested! Cross-reactivity reactivity (very poor with amphetamine, methylphenidate, l-methamphetamine) 3

Confirmatory Testing Gas Chromatography/Mass Spectrometry (GC/MS) utilized for confirmation Criteria for Confirmatory Testing Positive EMITs Drugs requested but not tested by EMIT screen! Specific GC/MS procedures are used to test for Cannabinoids, GHB, acidic drugs (e.g. Soma, Barbiturates), basic drugs (can identify a majority of the remaining drugs) Confirmatory Cutoffs Delta-9-tetrahydrocannabinol, tetrahydrocannabinol, 11-nor- delta-9-tetrahydrocannabinol-9-carboxylic carboxylic acid (both 8 ng/ml) GHB 10 μg/ml (Blood and Urine) Drugs not Detected by EMIT Screen Zolpidem (Ambien) Carisoprodol (Soma) Meprobamate Propoxyphene (Darvon, Darvocet) Promethazine (Phenergan) 3,4-Methylenedioxymethamphetamine (MDMA) Methamphetamine/Amphetamine Tramadol Antidepressants/Antipsychotics (Venlafaxine, Sertraline, Amitriptyline, Citalopram, Fluoxetine, Lamotrigine, Paroxetine, Quetiapine, Trazodone) Antihistamines (Diphenhydramine, Chlorpheniramine) 4

Drugs Not Tested in Blood Samples Heroin LSD/Psilocin/Psilocybin Fentanyl/Lorazepam/Clonazepam?? Clorazepate Analogs Lithium Hormones/proteins/natural products/steroids NSAIDs Heart/Blood Pressure medications Cannabinoids Cannabinoids (cont.) Cannabinoids undergo a redistribution from blood to fatty body tissue. Cannabinoid id blood presence or levels l do not correlate well with demonstrated impairment. 5

Cannabinoids (cont.) Indicators of use Odor of Marijuana about individual. Euphoria and relaxation Lack of concentration Altered perception of time Reddened conjuctiva Increased heart rate Decreased respiratory rate Cocaine Few scientific studies on the direct effects of cocaine on driving performance. Only low doses studied. Can reverse the performance decrements of depressant drugs. May give driver feeling of increased mental and physical abilities. Cocaine (cont.) May result in increased risk taking behavior. High speed chases with police. Road rage. Effects are brief (30 minutes) 6

Cocaine (cont.) Withdrawal (crash) period after acute cocaine use. Fatigue during this time may result in a particular dangerous time for driving. Cocaine Effects in Human Performance and Behavior, Isenschmid D. S., Foresnic Science Review, Vol. 14, January 2002. Supplied Questions In addition to committing the offense of DWI for driving with an alcohol concentration of 0.08 or with any amount of a Schedule I controlled substance in his blood or urine, a person is guilty of a DWI if he drives while under the influence of an impairing substance. N.C.G.S. 20-138.1. N.C.G.S.20-4.01(14a) defines impairing substance as Alcohol, controlled substance under Chapter 90 of the General Statutes, any other drug or psychoactive substance capable of impairing i i a person s physical or mental faculties, or any combination of these substances. The judges would like to know how (or if) they can connect behavior and performance on field sobriety tests with the presence of an impairing substance. 7

Yes, generally behavior and performance can be connected to the presence of impairing substances. There are three general groupings of psychoactive substances (DREs expand this list to seven classes): Stimulants (which speed up bodily functions, examples cocaine and methamphetamine), depressants essa (which slow down body functions examples es alcohol, o barbiturates, benzodiazepines, opiates, muscle relaxants, GHB, sedating antihistamines), and hallucinogens (examples LSD, MDMA). Some drugs may have more than one of these groupings. Some examples are 3,4-methylenedioxymethamphetamine (MDMA) which has both stimulant and hallucinogenic properties and ethanol, which is a depressant, has some stimulant effects at low doses. Stimulant effects will be exhibited with increased excitability, rapid pulse and breathing, sweating, high blood pressure, dilated pupils, possibly some hallucinations, paranoia. Depressants (sedatives, tranquilizers) effects range from slurred speech and general drowsiness to loss of motor skills to death from respiratory arrest. Hallucinogenic effects generally consist of unusual visual effects, unusual auditory effects, and unusual thoughts. Can observed behavior and performance be connected to the presence of impairing substances or is behavior and performance due to other factors (general tiredness, medical problems, just normal behavior)? Medical responders may be able to give an opinion relating to these issues. 8

The state may introduce into evidence at a DWI trial a lab report prepared by the SBI to demonstrate the presence of an impairing substance. If the substance found is a controlled substance under Chapter 90, then by definition it is an impairing substance. These reports often do not specify, however, whether the substance found is a controlled substance. The name listed on the lab report is often a trade name of the drug and is not specifically listed under Chapter 90 under the trade name. How can the District Court judge translate the trade name to the name listed in Chapter 90? Lab reports should now list a schedule if a substance is controlled under Chapter 90. Some drugs such as Butalbital and Meprobamate are present in preparations that may be controlled or in other preparations that are exempted by the DEA. See N.C.G.S. 90-88(i). Fiorinal Butalbital, Aspirin, Caffeine Schedule III preparation Fioricet Butalbital, Acetaminophen, Caffeine noncontrolled, DEA exempt preparation. In addition schedules are not listed when a controlled substance may be listed in different schedules (example preparations of less 15 milligrams of Hydrocodone (Dihydrocodeinone) that contain one or more active, nonnarcotic ingredients in recognized therapeutic amounts are Schedule III N.C.G.S. 90-91(d)491(d)4 (Lortab and Vicodin), otherwise Hydrocodone is a Schedule II controlled substance). Lab reports should not list any trade names. Example received: Examination confirmed the presence of: promethazine propoxyphene. 9

Promethazine, not controlled under Chapter 90, common trade name Phenergan, used for anti-nausea, nausea, has a strong sedating effect. Propoxyphene 2 optical isomer forms (dextropropoxyphene and levopropoxyphene) Cannot differentiate isomer forms once in ingested Dextropropoxyphene, Schedule IV, common trade names Darvon, Darvocet, analgesic, may cause sedation. Levopropoxyphene, not listed in Chapter 90, not reported to have any analgesic effects, may have antitussive effects, no known trade names, virtually non-existent. Judges would also like to know whether all controlled substances are in fact impairing. Yes, except for the anabolic steroids. There are numerous reports that contain anecdotal evidence that anabolic steroids are associated with periods of anger (roid rage). Are other drugs that are not listed as a controlled substance in fact impairing substances? Yes. Diphenhydramine (Benadryl) and some other over the counter antihistamines have varying degrees of sedative effects. Carisoprodol (Soma), a common muscle relaxant, often causes drowsiness. Promethazine (Phernergan) can have very strong sedative effects. Dextromethorphan in over the counter cough syrups may have sedative effects. Certain individuals may have sedative effects from antidepressants. Inhalants (Psychoactive substance) 10

Can a judge tell anything about the level or concentration of drugs in the defendant s body from such a report? The SBI Laboratory currently only has quantitative methods for cannabinoids and GHB. For consistency all reports only report qualitative information. The immunoassay screens are semi-quantitative which allow for an estimate of concentration. Often concentration of a drug does not, in and of itself, allow an expert to form an opinion of an individual s condition. Judges also are interested in learning about any research that supports the testimony of drug recognition experts (DRE) identifying that a person has used an impairing substance. I am not a DRE Officer, and the North Carolina DRE program details would be better answered by a member of the DRE program. However, a DRE Officer should be able to provide for the court literature that supports the basis for their opinion for the particular drug class(es) that they have found for any case. and, DRE Officer should be able to also provide information regarding their personal training and experience in dealing with the particular drug class(es). 11

Questions? 12